News 2009

What Made the News in 2009

Study: Malignant Pheo, Paraganglioma, Metastatic Carcinoid

  • Molecular Insight Pharmaceuticals, Inc. has conducted a clinical trial to benefit patients with certain types of pheochromocytoma, paraganglioma or metastatic carcinoid tumors.
Note: This study is ongoing, but not recruiting participants.

The Pheo-Para Alliance announced a conference to be held in Parsippany, NJ on September 30 through October 2, 2009.

  • Dr. Karel Pacak was the main speaker on Pheochromocytoma: An overview of Research Achievements.
  •  Pheo-Para Alliance

Ann N Y Acad Sci. Author manuscript; available in PMC 2009 December 1.
Published in final edited form as:
Ann N Y Acad Sci. 2008 December; 1148: 462–468.
doi:  10.1196/annals.1410.081
PMCID: PMC2693284
NIHMSID: NIHMS66489

  • Pheochromocytoma: An Endocrine Stress Mimicking Disorder
  • Vitaly Kantorovich,1 Graeme Eisenhofer,2 and Karel Pacak3
The publisher’s final edited version of this article is available at Ann N Y Acad Sci
Abstract

Pheochromocytoma is an endocrine tumor that can uniquely mimic numerous stress-associated disorders, with variations in clinical manifestations resulting from different patterns of catecholamine secretion and actions of released catecholamines on physiological systems.

Free full text  Author Manuscript:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693284/